Provided by Tiger Fintech (Singapore) Pte. Ltd.

Verastem

7.04
+0.830013.37%
Post-market: 7.040.00000.00%16:30 EDT
Volume:1.55M
Turnover:10.61M
Market Cap:362.49M
PE:-1.92
High:7.13
Open:6.33
Low:6.33
Close:6.21
Loading ...

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination With Defactinib for the Treatment of Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer

THOMSON REUTERS
·
31 Dec 2024

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Business Wire
·
31 Dec 2024

Analysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (CRVS), Healthcare Services (HCSG) and Verastem (VSTM)

TIPRANKS
·
21 Dec 2024

Analysts Conflicted on These Healthcare Names: Verastem (VSTM), Roche Holding AG (OtherRHHVF) and Cabaletta Bio (CABA)

TIPRANKS
·
21 Dec 2024

BRIEF-Applied Therapeutics Appoints John H. Johnson As Executive Chairman

Reuters
·
20 Dec 2024

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

THOMSON REUTERS
·
20 Dec 2024

Applied Therapeutics Inc - Les Funtleyder Appointed Interim CEO

THOMSON REUTERS
·
20 Dec 2024

Applied Therapeutics Inc - Shoshana Shendelman Steps Down as CEO

THOMSON REUTERS
·
20 Dec 2024

Verastem price target raised to $9 from $7 at Mizuho

TIPRANKS
·
19 Dec 2024

Verastem Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Dec 2024

Mizuho Raises Price Target on Verastem to $9 From $7, Keeps Outperform Rating

MT Newswires Live
·
18 Dec 2024

BRIEF-Verastem Oncology Provides A Clinical Update For Ramp 203 Trial

Reuters
·
18 Dec 2024

Verastem announces preliminary avutometinib and sotorasib data

TIPRANKS
·
18 Dec 2024

Verastem Inc - No Dose-Limiting Toxicities Observed in Triplet Combination

THOMSON REUTERS
·
18 Dec 2024

Verastem Oncology Provides a Clinical Update for Ramp 203 Trial in Advanced Kras G12c Mutant Non-Small Cell Lung Cancer

THOMSON REUTERS
·
18 Dec 2024

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Business Wire
·
18 Dec 2024

Mizuho Securities Keeps Their Buy Rating on Verastem (VSTM)

TIPRANKS
·
18 Dec 2024

Verastem’s Promising Drug Combination for LGSOC: Analyst Recommends Buy Rating

TIPRANKS
·
17 Dec 2024

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Business Wire
·
26 Nov 2024

Rpt-Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

THOMSON REUTERS
·
07 Nov 2024